PITTSBURGH, Feb. 25 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) today announced the appointment of John D. Sheehan as Executive Vice...
PITTSBURGH, Feb. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) announced today that it will host a conference call and live webcast on...
PITTSBURGH, Jan. 29 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received...
PITTSBURGH, Nov. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) today announced that Didier Barret, president of Mylan Europe, Middle East...
Mylan Inc. (MYL) swung to a third-quarter loss, weighed down by litigation and acquisition-related expenses, as its core operational performance...
By Val Brickates Kennedy U.S. drug stocks edged higher in early trading Thursday, with shares of biotech groups BioMarin Pharmaceutical Inc. and...
Mylan Inc. (MYL) swung to a third-quarter loss due to its $121 million settlement of a Medicaid-rebate case, masking higher generic drug revenue...
Three pharmaceutical companies agreed to a $124 million settlement to resolve claims they failed to pay rebates for some state Medicaid programs...
Mylan Inc. (MYL) and other drug makers have paid $124 million to settle charges that they underpaid their rebate obligations to state Medicaid...
_______________________________________________________________________________ FOR IMMEDIATE RELEASE CIV MONDAY, OCTOBER 19, 2009 (202) 514-2007...
By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
Mylan Inc. (MYL) said Monday it settled a dispute with the Department of Justice for $121 million over how it classified certain Medicaid rebates...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads